Chargement en cours...
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...
Enregistré dans:
| Publié dans: | Front Immunol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8206805/ https://ncbi.nlm.nih.gov/pubmed/34149730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.689132 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|